Citations

Clear

3942 citation(s) found for "To, Van".

Induction Chemotherapy before Surgical Resection for Patients Presenting with Unresectable Esthesioneuroblastoma
Marinelli, John P. , Janus, Jeffrey R. , Link, Michael J., Choby, Garret , Miller, Kevin, Chintakuntlawar, Ashish V. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 6, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0039-1679417 Get It

Cardiac hypertrophy and arrhythmia in mice induced by a mutation in ryanodine receptor 2
Alvarado, Francisco , Yuchi, Zhiguang , Valdivia, Carmen R. , Hernández, Jonathan J. , Zhao, Yan-Ting , Henderlong, Dawn S., Booher, Talia R. , Marcou, Cherisse A. , Petegem, Filip Van , Ackerman, Michael J. , Valdivia, Héctor H. , Bos, J. Martijn , Henderlong, Dawn Shirley, Chen, Yan, Booher, Talia

Mayo Clinic

JCI Insight | March 5, 2019 | Volume: 4 | Issue: 7 | Pages: No page available

10.1172/jci.insight.126544 | PMID 30835254 Get It

Hypertrophic cardiomyopathy (HCM) is triggered mainly by mutations in genes encoding sarcomeric proteins, but a significant proportion of patients lack a genetic diagnosis. We identified a potentially novel mutation in ryanodine receptor 2, RyR2-P1124L, in a patient from a genotype-negative HCM cohort. The aim of this study was to determine whether RyR2-P1124L triggers functional and structural alterations in isolated RyR2 channels and whole hearts. We found that P1124L induces significant conformational changes in the SPRY2 domain of RyR2. Recombinant RyR2-P1124L channels displayed a cytosolic loss-of-function phenotype, which contrasted with a higher sensitivity to luminal [Ca 2+ ], indicating a luminal gain of function. Homozygous mice for RyR2-P1124L showed mild cardiac hypertrophy, similar to the human patient. This phenotype, evident at 1 year of age, was accompanied by an increase in the expression of calmodulin (CaM). P1124L mice also showed higher susceptibility to arrhythmia at 8 months of age, before the onset of hypertrophy. RyR2-P1124L has a distinct cytosolic loss-of-function and a luminal gain-of-function phenotype. This bifunctionally divergent behavior triggers arrhythmias and structural cardiac remodeling, and it involves overexpression of CaM as a potential hypertrophic mediator. This study is relevant to continue elucidating the possible causes of genotype-negative HCM and the role of RyR2 in cardiac hypertrophy.
Translabyrinthine Approach for Resection of Vestibular Schwannoma
Feng, Yening , Patel, Neil , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 1, 2019 | Volume: 80 | Issue: S 03 | Pages: S286-S286

10.1055/s-0039-1677856 | PMID 31143593 Get It

Objectives This video describes the surgical indications, relevant anatomy, and surgical steps of routine translabyrinthine surgery for gross total resection of sporadic vestibular schwannoma. Design The procedure is presented through a surgical instructional video. Setting The surgery took place at tertiary skull base referral center. Parcipant A 47-year-old patient reported with nonserviceable hearing, frequent episodes of vertigo, recurrent severe headache, and a small unilateral right sided vestibular schwannoma. Results Gross total resection with preservation of facial nerve function was achieved. Conclusion This instructional video documents the surgical steps and relevant anatomy for translabyrinthine resection of vestibular schwannoma.The link to the video can be found at: https://youtu.be/CJ2vKMLs7aI.
Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma
Rao, Dipti, Berkel, Anouk van , Piscaer, Ianthe, Gruber, Lucinda , Deutschbein, Timo , Beuschlein, Felix , Spyroglou, Ariadni , Prejbisz, Aleksander , Hanuš, K. , Eisenhofer, Graeme , Manelli, Massimo, Lenders, Jacques W.M. , Timmers, Henri , van Berkel, Anouk , Beuschlein, Felix , Rao, Dipti, Young, William F. , Faßnacht, Martin , Canu, Letizia , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 1, 2019 | Volume: 104 | Issue: 9 | Pages: 3812-3820

10.1210/jc.2018-02355 | PMID 30822354 Get It

Abstract Context Cross-sectional imaging with CT or MRI is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial. Objective To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL. Design International multicenter retrospective study. Intervention None. Patients Two hundred thirty-six unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal, and 26 metastatic PPGL. Main Outcome Measures Patients underwent both anatomical imaging (CT and/or MRI) and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses. Results The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively (P = 0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual treatment in four cases (1.2%: two metastatic instead of nonmetastatic, one multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1%: four metastatic instead of nonmetastatic, two multifocal instead of unifocal and one bilateral instead of unilateral adrenal). Conclusions For the initial localization of PPGL, the addition of 123I-MIBG scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.
Noncontrast Chest Computed Tomographic Imaging of Obesity and the Metabolic Syndrome
Schlett, Christopher L. , Nattenmüller, Johanna , Tsuchiya, Nanae , Vogel‐Claussen, Jens , Kauczor, Hans‐Ulrich , Levin, David L. , Hatabu, Hiroto , Estépar, Jose R., Wu, Ming-Ting , Levin, David, Beek, Edwin J.R. van , Schiebler, Mark , Vogel-Claussen, Jens

Mayo Clinic

Journal of Thoracic Imaging | February 28, 2019 | Volume: 34 | Issue: 2 | Pages: 116-125

10.1097/rti.0000000000000391 | PMID 30802234 Get It

There are physiological consequences of overeating that can lead to increased morbidity and mortality. The purpose of this review article is to acquaint the reader with the current state of the art in the non–cardiac-gated, noncontrast chest computed tomographic (NCCT) imaging biomarkers of the metabolic syndrome and their prognostic significance found in the lower neck and chest. NCCT imaging biomarkers associated with metabolic syndrome in the chest include premature coronary artery calcification, acceleration of large vessel arterial and valvular calcifications associated with atherosclerosis, and pulmonary arterial enlargement from pulmonary hypertension associated with sleep apnea. These easily identified imaging biomarkers have prognostic implications for major adverse cardiac events (MACE). These NCCT chest-imaging biomarkers are likely targets for artificial intelligence algorithms to harvest for longitudinal assessment of their individual and multifactorial contributions to chronic disease, MACE, and mortality. Early recognition and treatment of these common disorders may help improve patient outcomes and quality of life while decreasing medical costs.
Reassessing the impact of intraoperative electrocorticography on postoperative outcome of patients undergoing standard temporal lobectomy for MRI-negative temporal lobe epilepsy
Alvi, Mohammed Ali , Perkins, William J., Cascino, Gregory D. , Burkholder, David B. , So, Elson, Shin, Cheolsu, Marsh, Richard W., Meyer, Fredric B. , Burkholder, David B , Alvi, Mohammed Ali , Grewal, Sanjeet S. , Britton, Jeffrey W. , So, Elson L., Worrell, Gregory A. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | February 27, 2019 | Volume: 132 | Issue: 2 | Pages: 605-614

10.3171/2018.11.jns182124 | PMID 30797216 Get It

OBJECTIVEAlmost 30% of the patients with suspected temporal lobe epilepsy (TLE) have normal results on MRI. Success rates for resection of MRI-negative TLE are less favorable, ranging from 36% to 76%. Herein the authors describe the impact of intraoperative electrocorticography (ECoG) augmented by opioid activation and its effect on postoperative seizure outcome.METHODSAdult and pediatric patients with medically resistant MRI-negative TLE who underwent standardized ECoG at the time of their elective anterior temporal lobectomy (ATL) with amygdalohippocampectomy between 1990 and 2016 were included in this study. Seizure recurrence comprised the primary outcome of interest and was assessed using Kaplan-Meier and multivariable Cox regression analysis plots based on distribution of interictal epileptiform discharges (IEDs) recorded on scalp electroencephalography, baseline and opioid-induced IEDs on ECoG, and extent of resection.RESULTSOf the 1144 ATLs performed at the authors’ institution between 1990 and 2016, 127 (11.1%) patients (81 females) with MRI-negative TLE were eligible for this study. Patients with complete resection of tissue generating IED recorded on intraoperative ECoG were less likely to have seizure recurrence compared to those with incomplete resection on univariate analysis (p < 0.05). No difference was found in seizure recurrence between patients with bilateral independent IEDs and unilateral IEDs (p = 0.15), presence or absence of opioid-induced epileptiform activation (p = 0.61), or completeness of resection of tissue with opioid-induced IEDs on intraoperative ECoG (p = 0.41).CONCLUSIONSThe authors found that incomplete resection of IED-generating tissue on intraoperative ECoG was associated with an increased chance of seizure recurrence. However, they found that induction of epileptiform activity with intraoperative opioid activation did not provide useful intraoperative data predictive of improving operative results for temporal lobectomy in MRI-negative epilepsy.
Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies
Flores, Shaney , Wang, Guoqiao , Hornbeck, Russ C. , Speidel, Benjamin , Joseph‐Mathurin, Nelly , Vlassenko, Andrei G. , Gordon, Brian A. , Klunk, William E. , Jack, Clifford R. , Farlow, Martin R. , Salloway, Stephen , Snider, Barbara J., Berman, Sarah , Roberson, Erik D. , Brosch, Jared R. , Jimenez-Velazques, Ivonne, Dyck, Christopher H. van , Yuan, Shauna H. , Jayadev, Suman , Gauthier, Serge , Hsiung, Ging‐Yuek Robin , Brooks, William S. , Fulham, Michael , Clarnette, Roger, Masters, Colin L. , Wallon, David , Hannequin, Didier , Dubois, Bruno , Pariente, Jérémie , Sánchez‐Valle, Raquel , Mummery, Catherine J. , Ringman, John M. , Klein, Gregory , Milosavljevic‐Ristic, Smiljana, Morris, John C. , Bateman, Randall J. , Jack, Clifford R , Gordon, Brian A , Hsiung, Gink-Yuek , Roberson, Erik , Sánchez-Valle, Raquel , Bateman, Randall J , Masters, Colin L , Joseph-Mathurin, Nelly , Morris, John C , Brooks, William , Su, Yi , Koeppe, Robert A. , Galasko, Douglas , Honig, Lawrence S. , Masellis, Mario , Bottlaender, Michel , McDade, Eric , Xiong, Chengjie , Benzinger, Tammie L.S. , Berman, Sarah

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | February 23, 2019 | Volume: 11 | Issue: 1 | Pages: 180-190

10.1016/j.dadm.2018.12.008 | PMID 30847382 Get It

Abstract Introduction Quantitative in vivo measurement of brain amyloid burden is important for both research and clinical purposes. However, the existence of multiple imaging tracers presents challenges to the interpretation of such measurements. This study presents a direct comparison of Pittsburgh compound B–based and florbetapir‐based amyloid imaging in the same participants from two independent cohorts using a crossover design. Methods Pittsburgh compound B and florbetapir amyloid PET imaging data from three different cohorts were analyzed using previously established pipelines to obtain global amyloid burden measurements. These measurements were converted to the Centiloid scale to allow fair comparison between the two tracers. The mean and inter‐individual variability of the two tracers were compared using multivariate linear models both cross‐sectionally and longitudinally. Results Global amyloid burden measured using the two tracers were strongly correlated in both cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer. The variability may be partially caused by white matter signal as partial volume correction reduces the variability and improves the correlations between the two tracers. Amyloid burden measured using both tracers was found to be in association with clinical and psychometric measurements. Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was detected in the average annualized rate of change measurements made with these two tracers. Discussion Although the amyloid burden measurements were quite similar using these two tracers as expected, difference was observable even after conversion into the Centiloid scale. Further investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired using different tracers.
Effect of Lidocaine on Viability and Gene Expression of Human Adipose–derived Mesenchymal Stem Cells: An in vitro Study
Nie, Hai , Kubrova, Eva , Denbeigh, Janet M. , Dietz, Allan B. , Smith, Jay , Qu, Wenchun , Wijnen, André J. van , Hunt, Christine , van Wijnen, Andre J , Dietz, Allan B , Wu, Tao , Hunt, Christine

Mayo Clinic

PM&R | February 20, 2019 | Volume: 11 | Issue: 11 | Pages: 1218-1227

10.1002/pmrj.12141 | PMID 30784215 Get It

ObjectiveTo assess the biologic effects of lidocaine on the viability, proliferation, and function of human adipose tissue–derived mesenchymal stromal/stem cells (MSCs) in vitro.MethodsAdipose‐derived MSCs from three donors were exposed to lidocaine at various dilutions (2 mg/mL to 8 mg/mL) and exposure times (0.5 to 4 hours). Cell number and viability, mitochondrial activity, and real‐time reverse‐transcriptase quantitative polymerase chain reaction (RT‐qPCR) were analyzed at 0 (immediate effects) or 24 and 48 hours (recovery effects) after treatment with lidocaine.ResultsTrypan blue staining showed that increasing concentrations of lidocaine decreased the number of observable viable cells. 3‐[4,5,dimethylthiazol‐2‐yl]‐5‐[3‐carboxymethoxy‐phenyl]‐2‐[4‐sulfophenyl]‐2H‐tetrazolium (MTS) assays revealed a concentration‐ and time‐ dependent decline of mitochondrial activity and proliferative ability. Gene expression analysis by RT‐qPCR revealed that adipose‐derived MSCs exposed to lidocaine express robust levels of stress response/cytoprotective genes. However, higher concentrations of lidocaine caused a significant downregulation of these genes. No significant differences were observed in expression of extracellular matrix (ECM) markers COL1A1 and DCN except for COL3A1 (P < .05). Levels of messenger RNA (mRNA) for proliferation markers (CCNB2, HIST2H4A, P < .001) and MKI67 (P < .001) increased at 24 and 48 hours. Expression levels of several transcription factors— including SP1, PRRX1, and ATF1—were modulated in the same manner. MSC surface markers CD44 and CD105 demonstrated decreased expression immediately after treatment, but at 24 and 48 hours postexposure, the MSC markers showed no significant difference among groups.ConclusionLidocaine is toxic to MSCs in a dose‐ and time‐ dependent manner. MSC exposure to high (4‐8 mg/mL) concentrations of lidocaine for prolonged periods can affect their biologic functions. Although the exposure time in vivo is short, it is essential to choose safe concentrations when applying lidocaine along with MSCs to avoid compromising the viability and potency of the stem cell therapy.
Canstem111P Trial: A Phase Iii Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine
Sonbol, Mohamad Bassam , Ahn, Daniel H. , Goldstein, David , Tabernero, Josep , Macarulla, Teresa , Reni, Michele , O’Neil, Bert H. , Bekaii‐Saab, Tanios , Sonbol, Mohamad B , Tabernero, Josep , Bekaii-Saab, Tanios S , Okusaka, Takuji , Li, Chung‐Pin , Cutsem, Eric Van , Macarulla, Teresa

Mayo Clinic

Future Oncology | February 15, 2019 | Volume: 15 | Issue: 12 | Pages: 1295-1302

10.2217/fon-2018-0903 | PMID 30768369 Get It